Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Modeling Fanconi anemia pathogenesis and therapeutics using integration-free patient iPSCs

  • Liu, Guang-Hui
  • Suzuki, Keiichiro
  • Li, Mo
  • Qu, Jing
  • Montserrat, Núria
  • Tarantino, Carolina|||0000-0003-2470-3803
  • Gu, Ying
  • Yi, Fei
  • Xu, Xiuling
  • Zhang, Weiqi|||0000-0002-2535-1398
  • Ruiz, Sergio
  • Plongthongkum, Nongluk
  • Zhang, Kun
  • Masuda, Shigeo
  • Nivet, Emmanuel
  • Tsunokawa, Yuji
  • Soligalla, Rupa Devi
  • Goebl, April
  • Aizawa, Emi
  • Kim, Na Young
  • Kim, Jessica
  • Dubova, Ilir
  • Li, Ying|||0000-0002-5377-6262
  • Ren, Ruotong
  • Benner, Chris
  • Sol, Antonio del
  • Bueren, Juan|||0000-0002-3228-7013
  • Trujillo Quintero, Juan Pablo
  • Surralles, Jordi|||0000-0002-4041-7519
  • Cappelli, Enrico
  • Dufour, Carlo
  • Rodriguez Esteban, Concepción
  • Izpisúa Belmonte, Juan Carlos
Fanconi anaemia (FA) is a recessive disorder characterized by genomic instability, congenital abnormalities, cancer predisposition and bone marrow (BM) failure. However, the pathogenesis of FA is not fully understood partly due to the limitations of current disease models. Here, we derive integration free-induced pluripotent stem cells (iPSCs) from an FA patient without genetic complementation and report in situ gene correction in FA-iPSCs as well as the generation of isogenic FANCA-deficient human embryonic stem cell (ESC) lines. FA cellular phenotypes are recapitulated in iPSCs/ESCs and their adult stem/progenitor cell derivatives. By using isogenic pathogenic mutation-free controls as well as cellular and genomic tools, our model serves to facilitate the discovery of novel disease features. We validate our model as a drug-screening platform by identifying several compounds that improve hematopoietic differentiation of FA-iPSCs. These compounds are also able to rescue the hematopoietic phenotype of FA patient BM cells., Altres ajuts: Strategic Priority Research Program of the Chinese Academy of Sciences (XDA01020312), National Basic Research Program of China (973 Program,2014CB964600;2014CB910500), NSFC (81271266, 31222039, 81330008, 31201111, 81371342, 81300261, 81300677), Key Research Program of the Chinese Academy of Sciences (KJZD-EW-TZ-L05), Beijing Natural Science Foundation (7141005; 5142016), the Thousand Young Talents program of China, National Laboratory of Biomacromolecules (012kf02, 2013kf05;2013kf11;2014kf02), and State Key Laboratory of Drug Research (SIMM1302KF-17). M.L. and K.S. are supported by CIRM fellowship. N.M was partially supported by La Fundació Privada La Marató de TV3, 121430/31/32. Y.T. was partially supported by an Uehara Memorial Foundation research fellowship. E.N. was partially supported by an F.M. Kirby Foundation postdoctoral fellowship. J.S. was supported by Fundació Marató TV3 (464/C/2012). J.A.B. was supported by grants from La Fundació Privada La Marató de TV3, 121430/31/32. J.C.I.B. was supported by grants from the G. Harold and Leila Y. Mathers Charitable Foundation, The California Institute of Regenerative Medicine, Ellison Medical Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust grant #2012-PG-MED002.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted gene therapy and cell reprogramming in Fanconi anemia

  • Río, Paula
  • Baños, Rocío
  • Lombardo, Angelo
  • Quintana-Bustamante, Oscar|||0000-0002-6869-7006
  • Alvarez, Lara
  • Garate, Zita
  • Genovese, Pietro
  • Almarza, Elena
  • Valeri, Antonio
  • Díez, Begoña
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Torres, Yaima
  • Trujillo, Juan P.
  • Murillas, Rodolfo
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Samper, Enrique
  • Surralles, Jordi|||0000-0002-4041-7519
  • Gregory, Philip D.
  • Holmes, Michael C.
  • Naldini, Luigi
  • Bueren, Juan|||0000-0002-3228-7013
Gene targeting is progressively becoming a realistic therapeutic alternative in clinics. It is unknown, however, whether this technology will be suitable for the treatment of DNA repair deficiency syndromes such as Fanconi anemia (FA), with defects in homology-directed DNA repair. In this study, we used zinc finger nucleases and integrase-defective lentiviral vectors to demonstrate for the first time that FANCA can be efficiently and specifically targeted into the AAVS1 safe harbor locus in fibroblasts from FA-A patients. Strikingly, up to 40% of FA fibroblasts showed gene targeting 42 days after gene editing. Given the low number of hematopoietic precursors in the bone marrow of FA patients, gene-edited FA fibroblasts were then reprogrammed and re-differentiated toward the hematopoietic lineage. Analyses of gene-edited FA-iPSCs confirmed the specific integration of FANCA in the AAVS1 locus in all tested clones. Moreover, the hematopoietic differentiation of these iPSCs efficiently generated disease-free hematopoietic progenitors. Taken together, our results demonstrate for the first time the feasibility of correcting the phenotype of a DNA repair deficiency syndrome using gene-targeting and cell reprogramming strategies.